Percheron Therapeutics Limited
PERCF
$0.0025
-$0.0165-86.84%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 978.00K | 976.00K | -- |
| Total Other Revenue | 49.50K | 50.90K | -395.40K | -394.60K | 391.10K |
| Total Revenue | 49.50K | 50.90K | 582.60K | 581.40K | 391.10K |
| Cost of Revenue | 31.40K | 32.30K | 6.30K | 6.30K | 14.10K |
| Gross Profit | 18.10K | 18.60K | 576.30K | 575.10K | 377.00K |
| SG&A Expenses | 759.20K | 780.60K | 757.80K | 756.20K | 566.70K |
| Depreciation & Amortization | 11.80K | 12.10K | 10.60K | 10.50K | 15.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.81M | 2.89M | 2.95M | 2.94M | 1.94M |
| Operating Income | -2.76M | -2.83M | -2.36M | -2.36M | -1.54M |
| Income Before Tax | -2.78M | -2.86M | -2.36M | -2.36M | -1.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.78M | -2.86M | -2.36M | -2.36M | -1.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.78M | -2.86M | -2.36M | -2.36M | -1.55M |
| EBIT | -2.76M | -2.83M | -2.36M | -2.36M | -1.54M |
| EBITDA | -2.74M | -2.82M | -2.36M | -2.36M | -1.53M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 931.91M | 931.91M | 1.04B | 1.04B | 724.11M |
| Average Diluted Shares Outstanding | 931.91M | 931.91M | 1.04B | 1.04B | 724.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |